

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	Unassigned
Applicant	Wing CHEUNG et al.
Filed	24 March 2004
TC/Art Unit	Unassigned
Examiner	Unassigned

Docket No.	38081-00037
Customer No.	23767

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56(b)

Mail Stop Patent Application
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

In order to comply with Applicant's duty of disclosure pursuant to 37 C.F.R. §1.56, submitted herewith on Form PTO/SB/08A is a listing of documents known to Applicant. The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.


Applicant is submitting herewith on Form PTO/SB/08A a list of the documents cited by or submitted to the Patent Office in parent application Serial No. 09/569,612, filed on 10 May 2000.

As provided in 37 C.F.R. 1.98(d), copies of the documents are not being provided since they were previously cited by or submitted to the Patent Office in parent application Serial No. 09/569,612, filed on 10 May 2000.

Applicant respectfully requests that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. § 609.

This statement is being filed in compliance with 37 CFR §1.97(b), within three (3) month of the filing date of the application. Accordingly, no fee is required in connection with this filing. Nonetheless, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this paper to undersigned's Deposit Account No. 50-1067.

Respectfully submitted,



Don J. Pelto
Reg. No. 33,754

24 March 2004

Preston Gates Ellis & Rouvelas Meeds LLP
1735 New York Avenue NW, Suite 500
Washington, DC 20006
Tel. 202.628.1700
Fax. 202.331.1024

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Unassigned
				Filing Date	24 March 2004
				First Named Inventor	Wing CHEUNG et al.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	2	Attorney Docket Number	38081-00037

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	4,732,889	03/1988	CYN Shi et al.	
	A2	4,748,600	05/1988	URQUHART	
	A3	5,354,934	10/1994	PITT et al.	
	A4	5,416,071	05/1995	IGARI et al.	
	A5	5,541,158	07/1996	VANCE et al.	
	A6	5,674,534	10/1997	ZALE et al.	
	A7	5,739,277	04/1998	PRESTA et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A8	JP 2-96535	04/1990			√

1

Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A9	SALMONSON, T., "Pharmacokinetic and Pharmacodynamic Studies on Recombinant Human Erythropoietin," <i>J. Uro. Nephrol. Suppl.</i> 1990 0(129), pp 1-66 (Abstract) BIOSIS No. 1990:497818	
	A10	MATSUSHIA, et al., "A computer program (PPMODELS) with NeXTSTEP for calculating distribution of drugs based on physiological pharmacokinetic model," <i>Sch. Med., Kanazawa Univ</i> 1996 22(2) pp 123-132 (Abstract)	
	A11	PHYSICIANS DESK REFERENCE, 51 st ed. (1997) pp 489-495 Medical Economics Company, Inc., Montvale, NJ.	
	A12	WICHMANN, et al., "A mathematical model of erythropoiesis in mice and rats," <i>Cell Tissue Kinet</i> , (1989) 22(1) pp 31-49.	
	A13	COLBURN et al., "Pharmacokinetic Analysis of Drug Concentration Data Obtained during Repetitive Drug Administration," <i>J. Pharmaceutical Sci.</i> (1977) 66(4) 66 530-533	
	A14	WALTON, et al., "Computer support for determining drug dose systematic review and meta-analysis," <i>Brit. Medical Journal</i> (1999) 318 pp 984-990	
	A15	McMAHON, et al., "Pharmacokinetic and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers," <i>Blood</i> (1990) 76(9) pp 1718-1722	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Unassigned
				Filing Date	24 March 2004
				First Named Inventor	Wing CHEUNG et al.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	38081-00037

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A16	HU, et al., "Comparison of Some Control Strategies for Three-Compartment PK/PD Models," <i>J. of Pharmacokinetics and Biopharmaceutics</i> , Biopharmaceutics 1994 22(6) pp 525-550	
	A17	GOBBURU, "Role of dosage regimen in controlling indirect pharmacodynamic responses," <i>Adv. Drug Delivery Reviews</i> , (1998) 33 pp 221-233	
	A18	PORT, R.E. et al., "Predicting the time course of hemoglobin in children treated with erythropoietin for renal anemia," <i>Br. J. Clin. Pharmacol</i> (1998) 46(5) pp 461-466	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.